Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
about
Pazopanib in the management of advanced soft tissue sarcomasMore than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsFibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsTP53 mutational status is predictive of pazopanib response in advanced sarcomas.Treatment of Adult Soft Tissue Sarcomas: An OverviewDual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid TumorsThe clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma.Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case seriesMetastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two CasesRisk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis.Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study.Olaratumab for advanced soft tissue sarcoma.Advances in emerging drugs for osteosarcoma.Current and advancing systemic treatment options for soft tissue sarcomas.Phosphoproteomics in translational research: a sarcoma perspective.Chemotherapy for soft tissue sarcoma.Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.Synovial Sarcoma: Advances in Diagnosis and Treatment Identification of New Biologic Targets to Improve Multimodal Therapy.Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience.A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.Oncofertility in sarcoma patients.Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.[Primary renal angiosarcoma. Uncommon manifestation of a rare malignancy].
P2860
Q26746205-60A0FD09-924E-4696-A8A3-A833918EAF3CQ26781662-AEFDF09F-4C5C-4828-83D8-B368691EBDE8Q26801718-047EE393-8786-4C00-8EB0-B12F7916EA0FQ27853289-E22A7458-A539-47B8-AF0D-4AE7475A75C2Q28088685-6EE9EB25-03E5-446F-8C47-B73530A79F2FQ28822011-F0B69699-819D-4472-98F0-7CA2914D9373Q33430673-62325DC6-1B08-4F39-8097-A19370B9530BQ34264348-F93D08D0-FF35-4803-A191-238FF762BF2FQ34669352-3B0BE7EE-C8A3-4DBC-AE26-F9436A03892AQ34680171-C362D1B3-C158-450A-B7E1-E2570ABFB6D0Q36143478-2FC770F3-0AC1-4488-B541-575308CC2C9DQ37723943-62C0D6EF-B823-4201-A071-2E70BDEF6DACQ38365903-E720314D-E369-41BD-B25E-9BE9F7598CC2Q38377472-C1626843-F175-46B3-806D-6136630FC0B1Q38506118-B70A6214-12F2-425F-96EB-92C7F8FBD540Q38563242-75FE2B41-D56E-47D9-9515-5CB72CDFA8E4Q38708614-AE417EAB-655B-425B-92EC-A96624695560Q38902113-584D85D3-5F94-494D-B53E-D1AE63ACCF0EQ39191957-759E2F2F-5A69-4FB9-A076-B2B369C6D593Q39233440-C055D5E1-D338-4876-A93F-24862797C0B3Q39415429-7C99C0E3-5BE2-427B-8944-34B53BEBCB0AQ41105379-46A7074D-2C3F-4C2B-9024-C3D493DD6DB8Q41864217-C2DD5243-DD09-4383-B7E8-3DB6CA2A5A93Q42279324-159FF2C0-0993-40F6-AA37-BFDA2DE2A20DQ43993005-FFB24EE8-003F-4E01-A475-63121B28583AQ46688699-FD51892D-4F53-49EB-9EBD-08EF83C4377DQ47096741-60264685-108C-4545-BC27-D8E12D1C1574Q52671439-92546DBB-220A-4A7E-ADF2-5415643125CBQ53566843-EB24E1C7-3206-417B-BA9A-DBF27BC9FBD6
P2860
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Long-term responders and survi ...... inical trials 62043 and 62072.
@ast
Long-term responders and survi ...... inical trials 62043 and 62072.
@en
Long-term responders and survi ...... search and Treatment of Cancer
@nl
type
label
Long-term responders and survi ...... inical trials 62043 and 62072.
@ast
Long-term responders and survi ...... inical trials 62043 and 62072.
@en
Long-term responders and survi ...... search and Treatment of Cancer
@nl
prefLabel
Long-term responders and survi ...... inical trials 62043 and 62072.
@ast
Long-term responders and survi ...... inical trials 62043 and 62072.
@en
Long-term responders and survi ...... search and Treatment of Cancer
@nl
P2093
P2860
P356
P1433
P1476
Long-term responders and survi ...... inical trials 62043 and 62072.
@en
P2093
S Marreaud
S Sleijfer
W T A van der Graaf
P2860
P304
P356
10.1093/ANNONC/MDT586
P577
2014-02-06T00:00:00Z